BMY vs ABBV
BMY and ABBV side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BMYBristol-Myers Squibb Company | ABBVAbbVie Inc. |
|---|---|---|
| Market cap | $130.15B | $470.14B |
| P/E (TTM) | 17.9 | 131.1 |
| P/B | 6.49 | — |
| P/S | 2.7x | 7.6x |
| Dividend yield | 3.88% | 2.48% |
| Revenue | $48.48B(TTM) | $61.16B(TTM) |
| Revenue growth (YoY) | -0.2% | 8.6% |
| Net income | $7.28B(TTM) | $3.63B(TTM) |
| Earnings growth (YoY) | 178.8% | -1.2% |
| EPS, diluted | $3.57(TTM) | $2.03(TTM) |
| EBIT margin | 21.8% | 24.6% |
| ROE | 35.2% | — |
| ROIC | 14.4% | 20.0% |
| Piotroski F | 8/9 | — |
| 1y total return | +41.0% | +41.0% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BMY vs ABBV
| Metric | BMY | ABBV |
|---|---|---|
| End value | $14.6K | $72.8K |
| Total return | +46.1% | +628.0% |
| CAGR | +3.7% | +21.2% |
| Volatility | 25.2% | 25.8% |
| Sharpe | 0.12 | 0.73 |
| Sortino | 0.16 | 1.01 |
| Max drawdown | -47.7% | -45.1% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)